Cathie Wood's ARK increases Cerebras, cuts AMD stock

ARK Invest trims AMD and TSM holdings while expanding AI bets

Cathie Wood continued reshaping her firm's technology-focused portfolio this week as ARK Invest revealed a major new purchase in Cerebras Systems while reducing positions in several semiconductor and biotech companies.

According to ARK's latest daily trading disclosures published Friday, the investment firm made its largest move by purchasing 149,176 shares of Cerebras Systems across its ARKK and ARKW exchange-traded funds. The transaction carried a total value of roughly $46.4 million and marked another aggressive expansion of ARK's stake in the artificial intelligence hardware company.

The move follows a similar purchase made just one day earlier, signaling continued confidence in Cerebras as demand for AI infrastructure and computing power remains a central focus for investors.

1. ARK makes another major bet on Cerebras

Cerebras has increasingly become one of the more closely watched names in the AI sector due to its specialized chips and large-scale computing systems designed for artificial intelligence workloads.

ARK's latest purchase suggests Wood and her team see long-term growth potential in the company despite broader volatility across technology stocks. The investment firm has frequently leaned into emerging technologies and disruptive innovation themes, particularly in AI and advanced computing.

The latest buying spree reinforces ARK's strategy of building larger positions in companies tied to next-generation AI infrastructure as competition intensifies across the semiconductor industry.

2. AMD stake continues to shrink

While ARK increased its exposure to Cerebras, the firm simultaneously reduced its holdings in Advanced Micro Devices.

ARK sold 13,148 shares of AMD through its ARKW ETF in a transaction valued at approximately $5.9 million. The sale continues a broader pattern of reductions in the chipmaker throughout the week.

AMD has remained one of the most heavily followed semiconductor companies amid the AI boom, competing with rivals in data center and AI chip development. Even so, ARK's recent trading activity indicates the firm may be reallocating capital toward smaller or more specialized AI-focused companies instead of maintaining larger exposure to established semiconductor giants.

3. Taiwan Semiconductor and Teradyne also see cuts

Another major reduction involved Taiwan Semiconductor Manufacturing Company, often referred to as TSMC.

ARK sold 59,009 shares of the company across its ARKK and ARKW funds, with the transaction totaling nearly $24.7 million. The move extends a recent pattern of selling activity involving the chip manufacturing giant.

The investment firm also trimmed its position in Teradyne by selling 35,033 shares through its ARKK ETF. That trade was valued at roughly $12.5 million.

The Teradyne sale followed another reduction made earlier in the week, suggesting ARK is actively reshaping its semiconductor exposure as market conditions evolve.

4. Biotech holdings face additional adjustments

Beyond technology and chip stocks, ARK also adjusted several biotechnology positions.

The firm sold 6,356 shares of CareDx through its ARKG ETF. ARK also reduced its holdings in Twist Bioscience by selling 16,065 shares across multiple funds.

Though smaller in size compared to the semiconductor trades, the biotech sales highlight ongoing portfolio refinements within ARK's healthcare and genomics-focused investments.

ARK's latest transactions arrive during a period of heightened investor attention on artificial intelligence and semiconductor companies, with many firms racing to capitalize on AI-driven demand. Wood's strategy has often involved rotating aggressively into emerging technologies that she believes could dominate future markets.

The latest filings indicate ARK is doubling down on that approach by boosting its exposure to Cerebras while reducing positions in more established chip and biotech companies.

Disclaimer: This article is for informational purposes only and not financial advice. Always research before making investment decisions.

Source: Investing.com trade disclosures and ARK Invest daily trading data